Trials / Enrolling By Invitation
Enrolling By InvitationNCT06712017
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
A Descriptive, Retrospective, Single-Arm Cohort Study on the Use of Selective Internal Radiation Therapy (SIRT) with Yttrium-90 Microspheres for Unresectable Primary Hepatocellular Carcinoma (HCC) in the Chinese Population
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- GrandPharma (China) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China. Therefore, this retrospective real-world study is intented to explore the characteristics and efficacy of HCC patients treated with y90 in China, aiming to provide reference for guiding and optimizing clinical practices and subsequent confirmatory clinical studies for the treatment of HCC patients in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Yttrium-90 (Y-90) resin microspheres | selective internal radiation therapy |
Timeline
- Start date
- 2024-08-22
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
- First posted
- 2024-12-02
- Last updated
- 2024-12-05
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06712017. Inclusion in this directory is not an endorsement.